Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDC-APB in Healthy Volunteers
NCT02700373Phase 1Completed
- Sponsor
- Hapten Sciences
- Start
- Mar 2016
- Primary completion
- Jan 2018
- Modality
- Prophylactic Vaccines, Small Molecules, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in contact dermatitis comparing PDC-APB with Placebo (2 arms). Primary endpoint: Overall Safety Profile at 24 weeks. Started Mar 2016; status: completed.
02
Drugs
PDC-APB
03
Conditions
contact dermatitis
Beyond the preview
Go deeper on NCT02700373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02700373.